Published in Adv Cancer Res on January 01, 2008
Clearance of apoptotic cells: implications in health and disease. J Cell Biol (2010) 3.55
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature (2014) 3.45
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A (2009) 3.29
The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe (2012) 2.03
Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet (2011) 2.00
The retinal pigment epithelium in health and disease. Curr Mol Med (2010) 1.87
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther (2009) 1.78
Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J Immunol (2012) 1.77
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets (2010) 1.76
Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther (2010) 1.69
Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer. Proc Natl Acad Sci U S A (2013) 1.64
Biology of the TAM receptors. Cold Spring Harb Perspect Biol (2013) 1.59
AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res (2010) 1.50
Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation. J Hepatol (2015) 1.46
A novel approach identifies new differentially methylated regions (DMRs) associated with imprinted genes. Genome Res (2011) 1.45
Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden. PLoS One (2014) 1.39
The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus. J Virol (2010) 1.36
MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest (2013) 1.34
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U S A (2014) 1.34
Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene (2012) 1.33
Axl-dependent signalling: a clinical update. Clin Sci (Lond) (2012) 1.28
Molecular aspects of renal cell carcinoma: a review. Am J Cancer Res (2010) 1.25
Gonadotropin-releasing hormone (GnRH) neuron migration: initiation, maintenance and cessation as critical steps to ensure normal reproductive function. Front Neuroendocrinol (2010) 1.25
Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J Virol (2011) 1.23
Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. ACS Med Chem Lett (2012) 1.22
Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein. Virology (2011) 1.22
AXL mediates resistance to cetuximab therapy. Cancer Res (2014) 1.20
Vimentin: Central hub in EMT induction? Small GTPases (2011) 1.20
Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat (2011) 1.19
Filovirus tropism: cellular molecules for viral entry. Front Microbiol (2012) 1.18
The Mer receptor tyrosine kinase is expressed on discrete macrophage subpopulations and mainly uses Gas6 as its ligand for uptake of apoptotic cells. Clin Immunol (2009) 1.16
Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget (2011) 1.15
Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther (2012) 1.14
AXL kinase as a novel target for cancer therapy. Oncotarget (2014) 1.14
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther (2010) 1.12
Identification of Axl as a downstream effector of TGF-β1 during Langerhans cell differentiation and epidermal homeostasis. J Exp Med (2012) 1.10
Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells. PLoS One (2011) 1.09
Plasma protein growth arrest-specific 6 levels are associated with altered glucose tolerance, inflammation, and endothelial dysfunction. Diabetes Care (2010) 1.09
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene (2015) 1.07
Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene (2011) 1.07
Axl and Tyro3 modulate female reproduction by influencing gonadotropin-releasing hormone neuron survival and migration. Mol Endocrinol (2008) 1.06
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin Cancer Res (2013) 1.06
The tumor microenvironment: the making of a paradigm. Cancer Microenviron (2009) 1.06
Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. J Biol Chem (2014) 1.05
Growth arrest-specific protein 6 is hepatoprotective against murine ischemia/reperfusion injury. Hepatology (2010) 1.05
Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood (2010) 1.04
A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A (2009) 1.04
Filovirus entry: a novelty in the viral fusion world. Viruses (2012) 1.03
UNC1062, a new and potent Mer inhibitor. Eur J Med Chem (2013) 1.03
Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion. Mol Cell Biol (2014) 1.02
Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene (2013) 1.01
Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer J (2013) 1.00
Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood (2013) 1.00
Retracted Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood (2009) 1.00
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Mol Cancer Res (2012) 0.99
UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem (2014) 0.99
Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis. Arthritis Res Ther (2011) 0.99
MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme. Oncotarget (2014) 0.98
High glucose induces human endothelial dysfunction through an Axl-dependent mechanism. Cardiovasc Diabetol (2014) 0.98
Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity. J Biol Chem (2014) 0.97
Impaired apoptotic cell clearance in the germinal center by Mer-deficient tingible body macrophages leads to enhanced antibody-forming cell and germinal center responses. J Immunol (2010) 0.97
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clin Cancer Res (2015) 0.96
Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci (2013) 0.96
Disrupted Mer receptor tyrosine kinase expression leads to enhanced MZ B-cell responses. J Autoimmun (2010) 0.96
Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. J Med Chem (2013) 0.96
An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. Nat Chem Biol (2014) 0.96
Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. Hum Gene Ther Clin Dev (2013) 0.96
Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients. Ann Surg Oncol (2012) 0.95
MerTK regulates thymic selection of autoreactive T cells. Proc Natl Acad Sci U S A (2009) 0.95
MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J Clin Invest (2013) 0.94
TAM receptors in leukemia: expression, signaling, and therapeutic implications. Crit Rev Oncog (2011) 0.94
Emerging antibody combinations in oncology. MAbs (2011) 0.94
Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress. J Leukoc Biol (2009) 0.94
Pathways of oncogene-induced senescence in human melanocytic cells. Cell Cycle (2010) 0.93
Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus. PLoS One (2012) 0.93
Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget (2013) 0.92
Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma. PLoS One (2009) 0.92
TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system. Brain Res (2013) 0.91
Host cell factors in filovirus entry: novel players, new insights. Viruses (2012) 0.91
Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int J Mol Sci (2014) 0.91
Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. J Med Chem (2013) 0.91
Regulation of cancer stem cell activities by tumor-associated macrophages. Am J Cancer Res (2012) 0.90
A protective role of Mer receptor tyrosine kinase in nephrotoxic serum-induced nephritis. Clin Immunol (2010) 0.89
A novel role for c-Src and STAT3 in apoptotic cell-mediated MerTK-dependent immunoregulation of dendritic cells. Blood (2009) 0.89
Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene (2013) 0.89
Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells. PLoS One (2012) 0.88
The AXL Receptor is a Sensor of Ligand Spatial Heterogeneity. Cell Syst (2015) 0.88
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res (2015) 0.87
Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. Neoplasia (2014) 0.87
Hypothalamic but not pituitary or ovarian defects underlie the reproductive abnormalities in Axl/Tyro3 null mice. Mol Cell Endocrinol (2011) 0.87
Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling. Theranostics (2016) 0.87
UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther (2013) 0.86
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol (2010) 0.86
G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood (2014) 0.86
Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer. MAbs (2014) 0.85
Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer. Inflamm Bowel Dis (2014) 0.84
Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Reports (2015) 0.84
MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res (2013) 0.84
Serum growth arrest-specific protein 6 levels are a reliable biomarker of disease activity in systemic lupus erythematosus. J Clin Immunol (2012) 0.84
The hallmarks of cancer. Cell (2000) 113.05
Cell signaling by receptor tyrosine kinases. Cell (2000) 18.16
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature (2001) 6.31
Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Hum Mol Genet (2000) 4.42
Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science (2001) 4.42
The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell (1995) 4.13
Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med (2002) 3.83
Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat Genet (2000) 3.72
axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol (1991) 3.57
The protein tyrosine kinase family of the human genome. Oncogene (2000) 3.48
SOCS-1 participates in negative regulation of LPS responses. Immunity (2002) 3.39
SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity (2002) 3.25
Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature (1999) 2.80
cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci U S A (1999) 2.77
Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem (1996) 2.77
Synaptic adhesion molecules. Curr Opin Cell Biol (2003) 2.74
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med (2001) 2.66
Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J (2006) 2.49
An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron (1991) 2.47
Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J Immunol (2007) 2.45
Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature (1995) 2.45
A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood (2006) 2.41
A novel receptor tyrosine kinase, Mer, inhibits TNF-alpha production and lipopolysaccharide-induced endotoxic shock. J Immunol (1999) 2.26
Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ (1994) 2.17
Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev (2006) 2.16
Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nat Immunol (2006) 2.15
A role for Mer tyrosine kinase in alphavbeta5 integrin-mediated phagocytosis of apoptotic cells. J Cell Sci (2005) 2.15
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene (2007) 2.12
Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A (2006) 2.05
Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia (2005) 2.04
Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res (2005) 1.97
TAM receptor function in the retinal pigment epithelium. Mol Cell Neurosci (2006) 1.96
Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk. Proc Natl Acad Sci U S A (2001) 1.91
Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol (2002) 1.91
Cloning and developmental expression analysis of the murine c-mer tyrosine kinase. Oncogene (1995) 1.90
Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res (2005) 1.87
Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol (2002) 1.81
A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene (1991) 1.81
Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol (1997) 1.80
Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med (2006) 1.76
An RCS-like retinal dystrophy phenotype in mer knockout mice. Invest Ophthalmol Vis Sci (2003) 1.75
Retracted A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control. EMBO J (2005) 1.72
Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood (2006) 1.71
Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene (1997) 1.70
Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3. Cell (1995) 1.67
Promotion of the uptake of PS liposomes and apoptotic cells by a product of growth arrest-specific gene, gas6. J Biochem (2000) 1.64
Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol (2005) 1.62
MERTK arginine-844-cysteine in a patient with severe rod-cone dystrophy: loss of mutant protein function in transfected cells. Invest Ophthalmol Vis Sci (2004) 1.61
Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res (2006) 1.61
A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer (1995) 1.59
Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res (2002) 1.58
Macrophage regulation by Tyro 3 family receptors. Curr Opin Immunol (2003) 1.58
Structural basis for Gas6-Axl signalling. EMBO J (2005) 1.56
Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene (2006) 1.56
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest (2005) 1.55
Gas6 anti-apoptotic signaling requires NF-kappa B activation. J Biol Chem (2001) 1.53
The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem (1995) 1.52
Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol (1996) 1.50
Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy. Gene Ther (2005) 1.48
Protein kinase C regulates alpha v beta 5-dependent cytoskeletal associations and focal adhesion kinase phosphorylation. J Cell Biol (1996) 1.48
Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. J Biol Chem (1996) 1.47
Homozygous deletion in the coding sequence of the c-mer gene in RCS rats unravels general mechanisms of physiological cell adhesion and apoptosis. Neurobiol Dis (2000) 1.47
Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol (2005) 1.46
A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother (1992) 1.44
GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. J Biol Chem (1998) 1.44
Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol (2004) 1.42
Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer (1995) 1.41
Clinical significance of AXL kinase family in gastric cancer. Anticancer Res (2002) 1.40
Cell adhesion to phosphatidylserine mediated by a product of growth arrest-specific gene 6. J Biol Chem (1997) 1.40
Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene (1997) 1.38
Axl, a receptor tyrosine kinase, mediates flow-induced vascular remodeling. Circ Res (2006) 1.37
Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem (2003) 1.37
MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res (2001) 1.36
The growth arrest-specific gene product Gas6 promotes the survival of human oligodendrocytes via a phosphatidylinositol 3-kinase-dependent pathway. J Neurosci (2003) 1.36
The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol (1995) 1.36
Expression of the receptor protein-tyrosine kinases Tyro-3, Axl, and mer in the developing rat central nervous system. J Comp Neurol (2000) 1.36
Gas6/Axl signaling activates the phosphatidylinositol 3-kinase/Akt1 survival pathway to protect oligodendrocytes from tumor necrosis factor alpha-induced apoptosis. J Neurosci (2006) 1.34
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood (2001) 1.34
Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene (1997) 1.34
Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca(2+)-mobilizing growth factors. J Biol Chem (1995) 1.33
Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-kappaB. Mol Cell Biol (1999) 1.33
An SH2 domain-dependent, phosphotyrosine-independent interaction between Vav1 and the Mer receptor tyrosine kinase: a mechanism for localizing guanine nucleotide-exchange factor action. J Biol Chem (2003) 1.32
Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis (2003) 1.32
Retinal dystrophy due to paternal isodisomy for chromosome 1 or chromosome 2, with homoallelism for mutations in RPE65 or MERTK, respectively. Am J Hum Genet (2001) 1.32
Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. J Biol Chem (2005) 1.32
Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res (2004) 1.32
Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer (2001) 1.31
Transforming genes in chronic myelogenous leukemia. Proc Natl Acad Sci U S A (1988) 1.30
The mer receptor tyrosine kinase: expression and function suggest a role in innate immunity. Eur J Immunol (2003) 1.28
C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration. FASEB J (2005) 1.26
Clinical characterisation of a family with retinal dystrophy caused by mutation in the Mertk gene. Br J Ophthalmol (2006) 1.24
A putative receptor tyrosine kinase with unique structural topology. Oncogene (1991) 1.24
Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene (1994) 1.24
Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras. Oncogene (1999) 1.23
Coexpression of Gas6/Axl in human ovarian cancers. Oncology (2004) 1.23
Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res (2002) 1.22
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med (2002) 3.83
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J Immunol (2007) 2.45
A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood (2006) 2.41
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A (2007) 2.34
Successful treatment of severe aplastic anemia in children using standardized immunosuppressive therapy with antithymocyte globulin and cyclosporine A. Pediatr Blood Cancer (2004) 2.06
Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res (2005) 1.97
Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem (2002) 1.82
The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer (2014) 1.77
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets (2010) 1.76
An RCS-like retinal dystrophy phenotype in mer knockout mice. Invest Ophthalmol Vis Sci (2003) 1.75
Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood (2006) 1.71
Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther (2010) 1.69
Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res (2006) 1.61
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest (2005) 1.55
Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res (2005) 1.49
MerTK is required for apoptotic cell-induced T cell tolerance. J Exp Med (2008) 1.48
Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One (2010) 1.41
The p65/RelA subunit of NF-kappaB suppresses the sustained, antiapoptotic activity of Jun kinase induced by tumor necrosis factor. Mol Cell Biol (2002) 1.36
Natural killer cell neoplasms. Cancer (2008) 1.35
MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest (2013) 1.34
An SH2 domain-dependent, phosphotyrosine-independent interaction between Vav1 and the Mer receptor tyrosine kinase: a mechanism for localizing guanine nucleotide-exchange factor action. J Biol Chem (2003) 1.32
ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol (2009) 1.28
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res (2005) 1.24
The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol Biol Cell (2006) 1.23
Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. ACS Med Chem Lett (2012) 1.22
Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys (2004) 1.21
ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. J Mammary Gland Biol Neoplasia (2008) 1.20
Mer receptor tyrosine kinase signaling: prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation. J Biol Chem (2002) 1.19
Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J Biol Chem (2003) 1.17
Molecular pathways: MERTK signaling in cancer. Clin Cancer Res (2013) 1.16
Role of Gas6 in erythropoiesis and anemia in mice. J Clin Invest (2008) 1.16
Epithelial cell-directed efferocytosis in the post-partum mammary gland is necessary for tissue homeostasis and future lactation. BMC Dev Biol (2010) 1.11
The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation. Mol Endocrinol (2007) 1.05
Thymoma in children: report of 2 cases and review of the literature. Pediatr Dev Pathol (2010) 1.05
Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission. J Hematol Oncol (2013) 1.03
UNC1062, a new and potent Mer inhibitor. Eur J Med Chem (2013) 1.03
The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation. Mol Cell Biol (2008) 1.01
Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood (2013) 1.00
Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. J Clin Invest (2014) 1.00
Retracted Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood (2009) 1.00
UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem (2014) 0.99
MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme. Oncotarget (2014) 0.98
Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. J Med Chem (2013) 0.96
MerTK regulates thymic selection of autoreactive T cells. Proc Natl Acad Sci U S A (2009) 0.95
Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res (2003) 0.95
MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J Clin Invest (2013) 0.94
TAM receptors in leukemia: expression, signaling, and therapeutic implications. Crit Rev Oncog (2011) 0.94
Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Mol Cell Biol (2006) 0.94
Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress. J Leukoc Biol (2009) 0.94
Gray zone lymphomas in pediatric patients. Pediatr Dev Pathol (2010) 0.93
Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus. PLoS One (2012) 0.93
ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. J Clin Invest (2013) 0.92
Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res (2002) 0.92
Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. J Med Chem (2013) 0.91
Increased hematopoietic cells in the mertk-/- mouse peritoneal cavity: a result of augmented migration. J Immunol (2010) 0.89
A novel role for c-Src and STAT3 in apoptotic cell-mediated MerTK-dependent immunoregulation of dendritic cells. Blood (2009) 0.89
Capacitative calcium entry contributes to the differential transactivation of the epidermal growth factor receptor in response to thiazolidinediones. Mol Pharmacol (2007) 0.88
Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. Pediatr Blood Cancer (2009) 0.88
Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials. Curr Oncol Rep (2008) 0.88
Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunol Immunother (2004) 0.87
Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age. Pediatr Blood Cancer (2012) 0.86
UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther (2013) 0.86
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol (2010) 0.86
HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4. Cancer Res (2007) 0.85
Inherited retinal dystrophy in Mer knockout mice. Adv Exp Med Biol (2003) 0.85
Constitutive induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase deficient homocystinuria. Mol Genet Metab (2011) 0.83
The C-mer gene is induced by Epstein-Barr virus immediate-early protein BRLF1. J Virol (2004) 0.83
Defining the expressed breast cancer kinome. Cell Res (2012) 0.82
Transactivation of the EGF receptor: is the PDGF receptor an unexpected accomplice? Mol Interv (2002) 0.82
Research for North Carolina: The University Cancer Research Fund. N C Med J (2008) 0.82
Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation. Mol Endocrinol (2008) 0.81
TAM receptors are dispensable in the phagocytosis and killing of bacteria. Cell Immunol (2009) 0.79
Moderate aplastic anemia in children: preliminary outcomes for treatment versus observation from a single-institutional experience. J Pediatr Hematol Oncol (2013) 0.78
Dual ALK and MYC rearrangements leading to an aggressive variant of anaplastic large cell lymphoma. J Pediatr Hematol Oncol (2013) 0.78
Pre-clinical evaluation of tyrosine kinase inhibitors for treatment of acute leukemia. J Vis Exp (2013) 0.77
Precursor natural killer cell leukemia. Pediatr Blood Cancer (2008) 0.76